MinireviewNew approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin
Introduction
Chemotherapy is the main modality for systemic treatment of advanced or metastatic cancers and can also be applied as adjuvant to surgery and radiotherapy [7]. However, cancer chemotherapy is restricted by the toxicity of chemotherapeutic drugs and a more selective delivery of the cytotoxic agents to the primary tumors and their metastases would allow a dose escalation and reduce the peripheral toxicity.
Targeted chemotherapy represents a modern oncological strategy designed to improve the effectiveness of cytotoxic drugs and decrease peripheral toxicity. The receptors for peptide hormones on tumor cells can serve as targets for peptide ligands that can be linked to various cytotoxic agents. During the past 10 years we have synthesized and evaluated cytotoxic analogs of LHRH, somatostatin, and bombesin that can be targeted to various tumors [39], [41], [42], [43], [44], [56]. In this presentation we will review the antitumor effects of our cytotoxic analogs in experimental cancer models.
Section snippets
Cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH)
In the past 30 years, several thousand analogs of LHRH have been synthesized [24], [53], [54], [55], [57]. Agonistic analogs have found important clinical applications in gynecology and oncology. Potent antagonists of LHRH such as Cetrorelix have been also synthesized [53], [57].
The actions of LHRH analogs are mediated by receptors for LHRH found on the pituitary gonadotrophs [12], [53], [54], [55], [57]. The down-regulation of LHRH receptors, produced by sustained administration of LHRH
Cytotoxic somatostatin analogs
Potent octapeptide analogs of somatostatin including octreotide (Sandostatin) [2] and vapreotide (RC-160) [6] have been developed during the past 20 years. Somatostatin and its octapeptide analogs exert their effects through specific membrane receptors. Five distinct receptor subtypes (sst1–5) have been cloned and characterized [45]. Native somatostatin shows similar high affinity to sst1–5, but the synthetic octapeptides such as RC-160 and octreotide bind preferentially to sst2 and sst5.
Cytotoxic analogs of bombesin/gastrin releasing peptide
Gastrin-releasing peptide (GRP) has 27-amino acids and its carboxyl-terminal decapeptide is similar to that of tetradecapeptide bombesin [63]. GRP is widely distributed in lung and gastrointestinal tract, is produced in SCLC, breast, prostatic and pancreatic cancer and functions as growth factor [9], [53], [63]. Four receptor subtypes associated with the bombesin-like peptide family have been identified [9], [25], [39], [53].
The finding that bombesin or GRP can function as an autocrine growth
Strategies for therapy
Since the peptide receptors and mRNAs of receptor subtypes are variably expressed in diverse cancers, a careful determination of receptors and their subtypes in tumor tissue is required before therapy with cytotoxic analogs [53], [54]. Thus, biopsy samples of primary cancers and in some cases their metastases, should be subjected to ligand competition assays, Western Blots, and/or RT-PCR analyses for messenger ribonucleic acid (mRNA) expression of receptor subtypes. The tumors and their
References (67)
- et al.
SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
Life Sciences
(1982) - et al.
Antitumor effects of cytotoxic LHRH analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice
American Journal of Obstetrics and Gynecology
(2002) - et al.
High incidence of receptors for luteinizing hormone-releasing hormone (LH-RH) and LH-RH receptor gene expression in human prostate cancers
Journal of Urology
(2000) - et al.
Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high-affinity to human breast cancers
Cancer Letters
(1999) - et al.
A targeted cytotoxic somatostatin (SST) analogue AN-238 inhibits the growth of H-69 small cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice
European Journal of Cancer
(2001) - et al.
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice
American Journal of Obstetrics and Gynecology
(1999) - et al.
Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207
Cancer Letters
(2002) - et al.
Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA-PaCa-2 human pancreatic cancer xenografts in nude mice
Cancer Letters
(1992) - et al.
Hypothalamic hormones and cancer
Frontiers in Neuroendocrinology
(2001) Luteinizing hormone-releasing hormone analogs: Their impact on the control of tumorigenesis
Peptides
(1999)
Effective treatment of experimental ES-2 human ovarian cancers with cytotoxic analog of luteinizing hormone-releasing hormone AN-207
Anti Cancer Drugs
Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238
Proceedings of the National Academies of Science USA
Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer
Cancer Research
Potent bombesin antagonists with C-terminal Leu ψ(CH2N)-Tac-NH2 or its derivatives
Proceedings of the National Academy of Sciences USA
Synthesis and biological activity of highly potent octapeptide analogs of somatostatin
Proceedings of the National Academy of Sciences USA
Cancer chemotherapy
Principles and practice
Effective treatment of metastatic MDA-MD-435 human estrogen independent breast carcinomas with a targeted cytotoxic analog of luteinizing hormone-releasing hormone, AN-207
Clinical Cancer Research
Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer
Nature
Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop
Cancer Research
High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines
Cancer Research
The Use of Luteinizing Hormone-Releasing Hormone Agonists and Antagonists in Gynecological Cancers
Human Reproduction
Characteristics and distribution of receptors for peptide hormones and sex steroids in 500 biopsy samples of human breast cancer
Journal of Clinical Laboratory Analysis
High expression of somatostatin receptors and ribonucleic acid for its receptor subtypes in organ- confined and locally advanced human prostate cancers
Journal of Clinical Endocrinology and Metabolism
Human ovarian cancers express somatostatin receptors
Journal of Clinical Endocrinology and Metabolism
Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma
Cancer Research
Regression of Rat Dunning R-3327-H Prostate Carcinoma by Treatment with Targeted Cytotoxic Analog of Luteinizing Hormone-Releasing Hormone AN-207 Containing 2-Pyrrolinodoxorubicin
International Journal of Oncology
Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207
Cancer
Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice
Breast Cancer Research and Treatment
Inhibition of growth of MX-1, MCF-7, MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238
International Journal of Cancer
Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective
Endocrine Reviews
Targeted Cytotoxic analog of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice
British Journal of Cancer
Regression of U-87MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238
Clinical Cancer Research
Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study
Journal of the National Cancer Institute
Cited by (127)
Targeting nanoparticles to malignant tumors
2022, Biochimica et Biophysica Acta - Reviews on CancerNovel multifunctional nanocarrier-mediated codelivery for targeting and treatment of prostate cancer
2019, Nanomaterials for Drug Delivery and TherapyTargeting luteinizing hormone-releasing hormone: A potential therapeutics to treat gynecological and other cancers
2018, Journal of Controlled ReleaseA Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer
2017, Clinical Genitourinary CancerProstate cancer relevant antigens and enzymes for targeted drug delivery
2014, Journal of Controlled Release